iBio, Inc.

NASDAQ:IBIO

Biotechnology

Healthcare
$0.85 +0.00%

+$0.00 today

Market cap
$59.75M
Beta
1.29
P/E (TTM)
-3.6
EPS (TTM)
-$0.32
52W Low $0.78High $3.82

Volume 0.84M

Average 0.81M

IBIO Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

iBio, Inc.NASDAQ: IBIO

Weighted Avg Shares · Q4 FY2026 · quarter ended Jun 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q4 FY2026 weighted avg shares of 104.06M shares rose 533.6% year over year, behind the +753.1% change in trailing-twelve-month weighted avg shares. Sequentially, it fell 13.0% from the prior quarter. Over 3 fiscal years it compounded at +453.9% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +533.6% toward the trailing-twelve-month pace of +753.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
104.06M-13.0% QoQ
Last fiscal yearJun 2026
104.06M+891.1% YoY
LTMJun 2026
93.94M+753.1% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+533.6%——
1 year+891.1%——
3-year CAGR+453.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2026
104.06M USD
Year-over-year change
+891.1%
4-year CAGR
+778.9%

Weighted Avg Shares vs competitors

How IBIO compares with its peers on the latest reported figures

  • IBIO's LTM Jun 2026 weighted avg shares of 93.94M shares is the highest of the 4 companies compared; the peer median is 22.38M shares.
  • Its year-over-year change of +753.1% is the highest of 4, against a peer median of +4.3%.
  • Over three fiscal years its annual growth of +453.9% compares with a peer median of +12.3%.
IBIO Competitors Peer median
Weighted Avg Shares for IBIO and competitors
Company Period LTM YoY 3-year CAGR
IBIOiBio, Inc.LTM Jun 202693.94M +753.1%+453.9%
ANTXAN2 Therapeutics, Inc.LTM Mar 202631.18M +4.3%+25.4%
BOLDBoundless Bio, Inc.LTM Mar 202622.38M +7.1%+0.2%
RLYBRallybio CorporationLTM Mar 20265.55M -0.3%+12.3%
Peer median (excluding IBIO) 22.38M+4.3%+12.3%

Competitors are the stored peer set for IBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
FY2026
Jun 2026
Revenue1.88M0225K400K100K
Cost of Revenue3.79M0000
Gross Profit(1.91M)0225K400K100K
Gross Margin-101.2%—100.0%100.0%100.0%
Research & Development9.83M10.33M5.19M8.31M19.64M
Selling, General & Admin17.96M18.45M11.67M10.69M10.6M
Operating Expenses27.79M29.34M16.86M19M35.24M
Depreciation & Amortization3.79M1.38M1.25M1.13M646K
EBITDA(25.72M)(27.85M)(14.02M)(17.04M)(32.35M)
EBITDA Margin-1365.3%—-6231.6%-4259.8%-32345.0%
Operating Income(29.7M)(29.34M)(16.63M)(18.6M)(35.14M)
Operating Margin-1576.3%—-7392.9%-4650.5%-35141.0%
Interest Income177K213K363K437K2.15M
Interest Expense1.41M83K172K212K53K
Other Income / Expenses184K32K1.19M225K2.1M
Income Before Tax(29.51M)(29.31M)(15.44M)(18.38M)(33.04M)
Pre-Tax Margin-1566.5%—-6863.6%-4594.3%-33044.0%
Income Tax Expense00000
Net Income(50.39M)(65.01M)(24.91M)(18.38M)(33.04M)
Net Margin-2674.7%—-11069.8%-4594.3%-33044.0%
EPS (Basic)(2,889.06)(106.18)(6.50)(1.75)(0.32)
EPS (Diluted)(2,889.06)(106.18)(6.50)(1.75)(0.32)
Weighted Avg Shares17.44K612.25K3.83M10.5M104.06M
Weighted Avg Shares (Diluted)17.44K612.25K3.83M10.5M104.06M

iBio, Inc.

NASDAQ:IBIO

Intrinsic Alpha fair value

Locked

Current Price

$0.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.